From mesenchymal stem cells to their extracellular vesicles: Progress and prospects for asthma therapy

IF 10.7 1区医学 Q1 PHARMACOLOGY & PHARMACY

Asian Journal of Pharmaceutical Sciences Pub Date : 2024-08-01 DOI:10.1016/j.ajps.2024.100942

Shihan Chen , Jianqing Gao , Tianyuan Zhang

{"title":"From mesenchymal stem cells to their extracellular vesicles: Progress and prospects for asthma therapy","authors":"Shihan Chen , Jianqing Gao , Tianyuan Zhang","doi":"10.1016/j.ajps.2024.100942","DOIUrl":null,"url":null,"abstract":"<div><p>Asthma is a widespread public health concern, with an increasing incidence. Despite the implementation of current treatment strategies, asthma control, particularly for severe cases, remains suboptimal. Recent research has revealed the encouraging prospects of extracellular vesicles (EVs) secreted by mesenchymal stem cells (MSCs) as a viable therapeutic option for alleviating asthma symptoms. Therefore, the present review aims to provide an overview of the current progress and the therapeutic mechanisms of using MSC-derived EVs (MSC-EVs) for asthma treatment. Additionally, different administration approaches for EVs and their impacts on biodistribution and the curative outcomes of EVs are summarized. Notably, the potential benefits of nebulized inhalation of MSC-EVs are addressed. Also, the possibilities and challenges of using MSC-EVs for asthma treatment in clinics are highlighted. Overall, this review is intended to give new insight into the utilization of MSC-EVs as a potential biological drug for asthma treatment.</p></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"19 4","pages":"Article 100942"},"PeriodicalIF":10.7000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S181808762400059X/pdfft?md5=6dafc5f599cc1f51d447e88d5dffb6bb&pid=1-s2.0-S181808762400059X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S181808762400059X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Asthma is a widespread public health concern, with an increasing incidence. Despite the implementation of current treatment strategies, asthma control, particularly for severe cases, remains suboptimal. Recent research has revealed the encouraging prospects of extracellular vesicles (EVs) secreted by mesenchymal stem cells (MSCs) as a viable therapeutic option for alleviating asthma symptoms. Therefore, the present review aims to provide an overview of the current progress and the therapeutic mechanisms of using MSC-derived EVs (MSC-EVs) for asthma treatment. Additionally, different administration approaches for EVs and their impacts on biodistribution and the curative outcomes of EVs are summarized. Notably, the potential benefits of nebulized inhalation of MSC-EVs are addressed. Also, the possibilities and challenges of using MSC-EVs for asthma treatment in clinics are highlighted. Overall, this review is intended to give new insight into the utilization of MSC-EVs as a potential biological drug for asthma treatment.

Abstract Image

查看原文本刊更多论文

从间充质干细胞到细胞外囊泡：哮喘治疗的进展与前景

哮喘是一个普遍的公共卫生问题，发病率不断上升。尽管实施了当前的治疗策略，但哮喘的控制率，尤其是对严重病例的控制率仍不理想。最近的研究显示，间充质干细胞（MSCs）分泌的细胞外囊泡（EVs）作为缓解哮喘症状的一种可行治疗方案，前景令人鼓舞。因此，本综述旨在概述利用间充质干细胞衍生的细胞外小泡（MSC-EVs）治疗哮喘的当前进展和治疗机制。此外，还总结了EVs的不同给药方法及其对生物分布和EVs治疗效果的影响。值得注意的是，本文探讨了雾化吸入间充质干细胞-EVs 的潜在益处。此外，还强调了在临床中使用间充质干细胞-EVs 治疗哮喘的可能性和挑战。总之，本综述旨在为利用间充质干细胞-EVs 作为治疗哮喘的潜在生物药物提供新的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian Journal of Pharmaceutical Sciences Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

18.30

自引率

2.90%

发文量

审稿时长

14 days

期刊介绍： The Asian Journal of Pharmaceutical Sciences (AJPS) serves as the official journal of the Asian Federation for Pharmaceutical Sciences (AFPS). Recognized by the Science Citation Index Expanded (SCIE), AJPS offers a platform for the reporting of advancements, production methodologies, technologies, initiatives, and the practical application of scientific knowledge in the field of pharmaceutics. The journal covers a wide range of topics including but not limited to controlled drug release systems, drug targeting, physical pharmacy, pharmacodynamics, pharmacokinetics, pharmacogenomics, biopharmaceutics, drug and prodrug design, pharmaceutical analysis, drug stability, quality control, pharmaceutical engineering, and material sciences.